The judicious application of NGS in our diagnostic workflow proved particularly valuable when critical discriminative markers like HMGA2 were technically challenging to evaluate by immunohistochemistry, when the tumor’s retroperitoneal location expanded the differential diagnosis beyond typical vulvovaginal AMFB, and when molecular characterization offered potential therapeutic insights for atypical presentations. Here, HMGA2 is linked to neoplasm.